ArticleArchives of rheumatology2018
A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis.
Article in Archives of rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 77 citations in OpenAlex.
- Trial
- Trial
- Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial.Lupus science & medicine · 2023Trial
- Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.Annals of the rheumatic diseases · 2022Trial
- Factors associated with clinically significant nephritis in systemic lupus erythematosus patients who present with glomerular hematuria: a cross-sectional study.Rheumatology international · 2026Article
- Impact of race on comorbidity burden and clinical outcomes among Southeast Asians with lupus nephritis: a single-center retrospective study.International urology and nephrology · 2026Article
- IgG glycosylation dynamics in active lupus nephritis during the first year of immunosuppressive therapy.Frontiers in immunology · 2026Article
- Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases.Arthritis research & therapy · 2025Article
- Understanding Sex Differences in Autoimmune Diseases: Immunologic Mechanisms.International journal of molecular sciences · 2025Review
- Prognostic Factors of the Progression of Chronic Kidney Disease and the Development of End-Stage Renal Disease in Patients with Lupus Nephritis: A Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.Cureus · 2024Review
- Identifying distinct phenotypes of patients with juvenile systemic lupus erythematosus: results from a cluster analysis by the Egyptian college of rheumatology (ECR) study group.BMC pediatrics · 2024Article
- Lupus Nephritis from Pathogenesis to New Therapies: An Update.International journal of molecular sciences · 2024Review
- Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Treatment outcome and survival status among adult patients treated for lupus nephritis in selected tertiary hospitals of Ethiopia.Scientific reports · 2024Article
- Influence of Podocyte Injury on the Development of Class IV Lupus Nephritis.International journal of nephrology and renovascular disease · 2024Article
- Factors influencing self-management behaviors in persons with lupus nephritis: A cross-sectional study.Belitung nursing journal · 2024Article
- The Inflammatory and Oxidative Status of Newly Diagnosed Class III and Class IV Lupus Nephritis, with Six-Month Follow-Up.Antioxidants (Basel, Switzerland) · 2023Article
- Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares.Annals of the rheumatic diseases · 2023Observational
- Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention.Current rheumatology reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to conduct a meta-analysis to clarify the epidemiologic characteristics of biopsy-proven lupus nephritis (BPLN), including those relating to its prevalence and prognosis. PATIENTS AND
methodsA literature search for relevant studies was conducted in the electronic databases of PubMed, Google Scholar, Embase, and Cochrane trial register. The following search terms were used for original articles published between January 1982 and April 2016: "lupus nephritis" or systemic lupus erythematosus ('SLE') or 'systemic lupus erythematous' and "pathology" or 'epidemiology' or prevalence or incidence. Pooled estimates with 95% confidence intervals were calculated.
resultsNineteen studies were included (mean age of SLE patients at renal biopsy: ~30 years). Of total BPLN patients, 85% were females. BPLN developed in 29% of SLE patients, and accounted for 60% of secondary glomerular diseases in renal biopsy databases. BPLN prevalence among SLE patients was higher in Saudi Arabia compared with pooled Europe/USA data (43% vs 26%, p<0.05). Pooled BPLN prevalence among secondary glomerular diseases patients was higher in Asian/Latin American countries than in Europe (63% vs 34%, p<0.05). Overall five-, 10- and 20-year survival rates of BPLN patients were 94%, 86%, and 71%, respectively, which were higher than those before 1995 (84%, 72%, and 52%, respectively) and lower than those after 1995 (96%, 89%, and 80%, respectively) (all p<0.05). Class IV nephritis, present in 40% of BPLN patients, was a risk factor for renal failure that contributed to poor prognosis.
conclusionLupus nephritis is a common complication of young female patients with SLE, and the most prevalent etiology of secondary glomerular diseases. Attention should be paid to class IV nephritis due to its high frequency and association with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.